Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 2;10(11):a036855.
doi: 10.1101/cshperspect.a036855.

Interferon-Free Hepatitis C Virus Therapy

Jean-Michel Pawlotsky  1   2
Affiliations
Review

Interferon-Free Hepatitis C Virus Therapy

Jean-Michel Pawlotsky. Cold Spring Harb Perspect Med. .

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with ∼71 million chronically infected individuals worldwide. Treatment of patients with HCV-related liver disease has advanced considerably thanks to the development of new direct-acting antiviral drugs that are now administered as highly potent, safe, and well-tolerated combinations with a high barrier to resistance. International organizations, such as the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases jointly with the Infectious Diseases Society of America, or the World Health Organization have published detailed treatment guidelines. With these therapies becoming more and more widely available, elimination of hepatitis C as a public health threat by 2030 can now be envisaged in several countries. In other regions, better screening, diagnosis, and linkage to care will be necessary to achieve this ambitious goal.

PubMed Disclaimer

References

    1. ANRS Collaborative Study Group on Hepatocellular Carcinoma. 2016. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 65: 734–740. 10.1016/j.jhep.2016.05.045 - DOI - PubMed
    1. Bonacci M, Lens S, Londoño MC, Mariño Z, Cid MC, Ramos-Casals M, Sánchez-Tapias JM, Forns X, Hernández-Rodríguez J. 2017. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol 15: 575–583.e1. 10.1016/j.cgh.2016.09.158 - DOI - PubMed
    1. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, et al. 2017. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376: 2134–2146. 10.1056/NEJMoa1613512 - DOI - PubMed
    1. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, et al. 2019. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393: 1453–1464. 10.1016/S0140-6736(18)32111-1 - DOI - PubMed
    1. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, et al. 2015. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149: 649–659. 10.1053/j.gastro.2015.05.010 - DOI - PubMed

MeSH terms

LinkOut - more resources